A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

Exclusion Criteria

• •Patients who have received any chemotherapy for the treatment of pancreatic cancer prior to entering the study.
• •Previous treatment with any poly ADP-ribose polymerase (PARP) inhibitor.
• •Patients who have had radiotherapy or participated in another clinical trial with any investigational agents within 28 days of enrolment (Day 1 visit).
• •History of allergic reactions attributed to compounds of similar chemical or biologic composition to oxaliplatin, irinotecan, 5-Fluorouracil or other agents used in the study.
• •Previous treatment using CYP3A4 inducers within 3 weeks or inhibitors within 2 weeks of enrolment (Day 1 visit).
• •Patients with known or suspected brain metastasis.
• •Significant cardiovascular disease such as New York Heart Associate Class III/IV, cardiac failure, myocardial infarction, unstable arrhythmia, or evidence of ischemia on ECG within 6 months prior to enrolment.
• •Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
• •Patients with myelodysplastic syndrome/acute myeloid leukaemia.
• •Patients with second primary cancer except curatively treated in-situ cancer or slowly progressing malignancy.
• •Known active hepatitis B or C infection.
• •History of immunodeficiency (including HIV infection) or organ transplantation.
• •Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment.